Adjuvant trastuzumab: progress, controversies, and the steps ahead
2006
Adjuvant Trastuzumab: Progress and Controversies
Sample size: 1736
publication
Evidence: high
Author Information
Author(s): Joy A.A. MD, Mackey J.R. MD
Primary Institution: University of Alberta
Hypothesis
Can adjuvant trastuzumab improve outcomes for women with HER2-positive early-stage breast cancer?
Conclusion
Adjuvant trastuzumab significantly improves disease-free survival in patients with HER2-positive breast cancer.
Supporting Evidence
- Trastuzumab reduces the risk of cancer recurrence by 51% in one study.
- Patients receiving trastuzumab had a 39% reduction in recurrence risk in another trial.
- The combination of trastuzumab with chemotherapy improves overall survival rates.
Takeaway
Trastuzumab helps women with a specific type of breast cancer live longer without the cancer coming back.
Methodology
The study summarizes results from four major adjuvant trials involving trastuzumab in breast cancer treatment.
Limitations
The trials had varying designs and patient populations, making direct comparisons challenging.
Participant Demographics
Women with HER2-positive early-stage breast cancer.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 35% to 65%
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website